INCY•benzinga•
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
Summary
Incyte's povorcitinib met key Phase 3 trial endpoints in hidradenitis suppurativa, showing significant clinical response and a well-tolerated safety profile.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 17, 2025 by benzinga